Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Karin Björck"'
Autor:
Susanne Johansson, David Han, Thomas Hunt, Karin Björck, Delia Florica, Michael Gillen, Jesse Hall, Fredrik Erlandsson
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Verinurad is a selective inhibitor of uric acid transporter 1 (URAT1). Here, we assessed the safety, pharmacokinetics, and pharmacodynamics of verinurad + allopurinol and verinurad monotherapy in healthy participants. Studies 1 (NCT03836599)
Externí odkaz:
https://doaj.org/article/d64731bbf52f4f1998a9d8245b33bc2f
Autor:
Susanne Johansson, David Han, Thomas Hunt, Karin Björck, Delia Florica, Michael Gillen, Jesse Hall, Fredrik Erlandsson
Publikováno v:
Pharmacology researchperspectives. 10(3)
Verinurad is a selective inhibitor of uric acid transporter 1 (URAT1). Here, we assessed the safety, pharmacokinetics, and pharmacodynamics of verinurad + allopurinol and verinurad monotherapy in healthy participants. Studies 1 (NCT03836599) and 2 (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13043f13ec594f26e58854b692413d71
https://pubmed.ncbi.nlm.nih.gov/35593744
https://pubmed.ncbi.nlm.nih.gov/35593744
Autor:
Shira Perl, Karin Björck, Adriaan A. Voors, Fredrik Erlandsson, Robert J. Mentz, Dalane W. Kitzman, Gregory D. Lewis, Robin Myte, Sanjiv J. Shah
Publikováno v:
Journal of the American College of Cardiology. 77:597
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0af7229d057e8673bbec86e16e3cecf
https://doi.org/10.1016/s0735-1097(21)01956-2
https://doi.org/10.1016/s0735-1097(21)01956-2
Autor:
Hanneke Beaumont, Guy E. Boeckxstaens, Debra G. Silberg, Maria Karlsson, Jan Gunnar Hatlebakk, Hans Denison, Karin Björck
Publikováno v:
Gut, 60(9), 1182-1188. BMJ Publishing Group
Objective To evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastrooesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c345833b8e0ef2086423000e485169f8
https://doi.org/10.1136/gut.2010.235630
https://doi.org/10.1136/gut.2010.235630
Autor:
Lena Samuelsson, Annica Inerot, Karin Björck, Jan Wahlström, Staffan Nilsson, Camilla Friberg
Publikováno v:
Journal of Investigative Dermatology. 126:998-1002
We have previously reported a region on chromosome 5q as a possible susceptibility region for psoriasis. This cytokine cluster-rich region has also been suggested as a susceptibility locus in other autoimmune or inflammatory diseases including Crohn'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5f91eb984c13290e889918dccb166a
https://doi.org/10.1038/sj.jid.5700194
https://doi.org/10.1038/sj.jid.5700194
Autor:
Tommy Martinsson, Jonna Berggren, Staffan Nilsson, Margareta Nordling, Arne Wallgren, Annika Bergman, Jan Wahlström, Per Karlsson, Karin Björck
Publikováno v:
Genes, Chromosomes and Cancer. 46:302-309
The two breast cancer genes BRCA1 and BRCA2 were identified more than 10 years ago and, depending on population, mutations in these genes are responsible for a varying percentage of familial breast cancer. In more than half the families, the increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6f3bb3c0fa44eef04bccf1d2b41670a
https://doi.org/10.1002/gcc.20405
https://doi.org/10.1002/gcc.20405
Publikováno v:
The American journal of gastroenterology. 108(4)
Approximately 20-30% of patients with gastroesophageal reflux disease (GERD) do not experience complete symptom resolution during proton pump inhibitor (PPI) therapy. The aim of this study was to determine the prevalence of esophageal mucosal breaks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c178f21eecee88d1354b2e74ac3a10a
https://pubmed.ncbi.nlm.nih.gov/23318482
https://pubmed.ncbi.nlm.nih.gov/23318482
Autor:
Nimish Vakil, Anna Rydén, Jean Paty, Karin Björck, Maria Karlsson, Katarina Halling, Hans Denison, Debra G. Silberg
Publikováno v:
Clinical and Translational Gastroenterology
OBJECTIVES: We aimed to develop and validate the Reflux Symptom Questionnaire electronic Diary (RESQ-eD) for use in clinical trials in patients with a partial response to proton pump inhibitor (PPI) therapy, using methods that meet US Food & Drug Adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::346e1947878fc279e7c8ced43cbecd1c
https://pubmed.ncbi.nlm.nih.gov/23238029
https://pubmed.ncbi.nlm.nih.gov/23238029
Publikováno v:
Gut. 62(9)
Lesogaberan (AZD3355) is a novel γ-aminobutyric acid B-type receptor agonist designed to treat gastro-oesophageal reflux disease (GERD) by inhibiting transient lower oesophageal sphincter relaxations. A randomised, double-blind, placebo-controlled,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b254998b27eb3f2a39420d9b8d0956
https://pubmed.ncbi.nlm.nih.gov/22730470
https://pubmed.ncbi.nlm.nih.gov/22730470
The pathophysiology underlying the nephrotic syndrome is becoming clear for several inherited podocytopathies; the mechanisms of injury that lead to the acquired forms of this disease are not well understood. We explored these mechanisms using the mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baec0187e3c927602a5b19492ed71929
https://europepmc.org/articles/PMC2615716/
https://europepmc.org/articles/PMC2615716/
